Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert
Xiaoqi Li, Mansi Gulati, Alaina C. Larson, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 14-27
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Therapeutic resistance to anti-oestrogen therapy in breast cancer
Marie Will, Jackson Liang, Ciara Metcalfe, et al.
Nature reviews. Cancer (2023) Vol. 23, Iss. 10, pp. 673-685
Open Access | Times Cited: 59
Current and future immunotherapeutic approaches in pancreatic cancer treatment
Pooya Farhangnia, Hossein Khorramdelazad, Hamid Nickho, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 34
Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept
Wenyu Luo, Ti Wen, Xiujuan Qu
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 24
Epigenetic regulation in cancer
Minzhi Gu, Bo Ren, Yuan Fang, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 17
Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma
Shailendra K. Gautam, Surinder K. Batra, Maneesh Jain
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 39
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 15
The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer
Vishnu Kumarasamy, Jianxin Wang, Costakis Frangou, et al.
Cancer Research (2024) Vol. 84, Iss. 7, pp. 1115-1132
Open Access | Times Cited: 14
Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies
D.Y. Luo, Jing Zhou, Shuiliang Ruan, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Antibody drug conjugates: hitting the mark in pancreatic cancer?
Nicole L. Wittwer, Michael P. Brown, Vasilios Liapis, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 16
The Role of Tumor Microenvironment in Pancreatic Cancer Immunotherapy: Current Status and Future Perspectives
Fotini Poyia, Christiana M. Neophytou, Maria Christodoulou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9555-9555
Open Access | Times Cited: 4
A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in pancreatic cancer
Saskia Hussung, Dilara Akhoundova, Clelia Pistoni, et al.
ESMO Gastrointestinal Oncology (2025) Vol. 7, pp. 100134-100134
Closed Access
An Analysis of the mRNA Expression of Peripheral-Blood Stem and Progenitor Cell Markers in Pancreatic Neoplastic Disorders
Krzysztof Dąbkowski, Maciej Tarnowski, Krzysztof Safranow, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 4, pp. 236-236
Open Access
Ensemble machine learning and tree-structured Parzen estimator to predict early-stage pancreatic cancer
Kah Keng Wong
Biomedical Signal Processing and Control (2025) Vol. 108, pp. 107867-107867
Closed Access
Knocking down GALNT6 promotes pyroptosis of pancreatic ductal adenocarcinoma cells through NF-κB/NLRP3/GSDMD and GSDME signaling pathway
Mengyang Ding, Jingyu Liu, Honghui Lv, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 10
Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges
Zhichen Jiang, Xiaohao Zheng, Min Li, et al.
Frontiers of Medicine (2023) Vol. 17, Iss. 6, pp. 1135-1169
Closed Access | Times Cited: 10
Stromal and tumor immune microenvironment reprogramming through multifunctional cisplatin-based liposomes boosts the efficacy of anti-PD-1 immunotherapy in pancreatic cancer
Hang Yu, Wenting Zhu, Caiyan Lin, et al.
Biomaterials Science (2023) Vol. 12, Iss. 1, pp. 116-133
Closed Access | Times Cited: 8
Stereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Clinical CA209-9KH Trial
Milan Vošmik, Stanislav John, Josef Dvořák, et al.
Oncology and Therapy (2024) Vol. 12, Iss. 4, pp. 817-831
Open Access | Times Cited: 2
The deubiquitinating enzyme MINDY2 promotes pancreatic cancer proliferation and metastasis by stabilizing ACTN4 expression and activating the PI3K/AKT/mTOR signaling pathway
Peng Liu, Songbai Liu, Changhao Zhu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 6
Reprogramming of cancer-associated fibroblasts combined with immune checkpoint inhibitors: A potential therapeutic strategy for cancers
Min Li, Baokang Wu, Lunxu Li, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 5, pp. 188945-188945
Closed Access | Times Cited: 6
The application of pancreatic cancer organoids for novel drug discovery
Michael Karl Melzer, Yazid J. Resheq, Fatemeh Navaee, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 4, pp. 429-444
Closed Access | Times Cited: 4
CARD9 deficiency promotes pancreatic cancer growth by blocking dendritic cell maturation via SLC6A8-mediated creatine transport
Cheng Tian, Huimin Yuan, Yi Lu, et al.
OncoImmunology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 4
Current Clinical Landscape of Immunotherapeutic Approaches in Pancreatic Cancer Treatment
Pooya Farhangnia, Shamim Mollazadeh Ghomi, Shabnam Mollazadehghomi, et al.
(2023), pp. 327-380
Closed Access | Times Cited: 4
Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
Shiyun Chen, Lu Han, Shiyuan Guo, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 4
BCL2L1 is regulated by the lncRNA MIR4435-2HG-miR-513a-5p-BCL2L1 ceRNA axis and serves as a biomarker for pancreatic adenocarcinoma treatment and prognosis
Rongkun Zhu, Hongjian Zhou, Wei J. Chen, et al.
Gene (2024) Vol. 925, pp. 148615-148615
Open Access | Times Cited: 1
Pharmacologically targeting KRASG12Din PDAC models: tumor cell intrinsic and extrinsic impact
Vishnu Kumarasamy, Costakis Frangou, Jianxin Wang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top